



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Semorinemab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99399   |
| CAS No.:  | 2159141-27-0  |
| Target:   | Tau Protein   |
| Pathway:  | Neuronal Signaling  |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |   |   |
|--------------------|---|---|
| <b>Description</b> | Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a $K_d$ value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease <sup>[1]</sup> .                |   |
| <b>In Vitro</b>    | Semorinemab binds to human Tau and recombinant cynomolgus monkey Tau with $K_d$ values of 3.8 and 11.2 nM, respectively <sup>[1]</sup> .<br>Semorinemab prevents neurons to uptake oligomeric Tau <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |   |
| <b>In Vivo</b>     | Semorinemab (3, 10 and 30 mg/kg; i.p., once weekly for 13 weeks) reduces accumulation of Tau pathology in a transgenic (Tg) mouse model of tauopathy <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |   |
|                    | Animal Model:   | Tg mouse with the expression of human disease-causing tau mutant (TauP301L-Tg) <sup>[1]</sup>             |
|                    | Dosage:   | 3, 10 and 30 mg/kg  |
|                    | Administration:   | Intraperitoneal injection; 3, 10 and 30 mg/kg, once weekly for 13 weeks                                   |
|                    | Result:   | Reduced the accumulation of pathological tau, and dose-dependently decreased pTau212/214 and pTau202/205. |

### REFERENCES

[1]. Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. *Sci Transl Med.* 2021 May 12;13(593):eabb2639.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA